Action Calls: Petmed Express Inc. (PETS) v2

Top Small Cap Growth/ momentum Play (Growth BUY rated: multi-factor Quant “Smart” Screen)

Buy: Petmed Express Inc. (PETS)

Recent price: $43.41

Model projected value:  $47*


Petmed Express Inc. (PETS) recent price $43.41: PetMed Express, Inc. (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies. Its products include brands of medication, such as Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution and Rimadyl. It also offers additional pet supplies for sale on its Website, which are drop shipped to its customers by third parties. These pet supplies include food, beds, crates, stairs, strollers and other pet supplies. Its products included Non-Prescription Medications (Over the Counter (OTC)) and supplies, and Prescription Medications (Rx). Its customers are located in California, Florida, Texas, New York, Virginia and Georgia, among others.

PETS has a recent history of beating earnings estimates, followed by favorable price momentum


PETS analysts raised eps estimates again. PETS has a very high analysts revision factor score.


This Quarter (FQ Sep-17)                 This Year (FY Mar-18)                       Next Year (FY Mar-19)

Measure Component Percentile                       Blended Mean Change      Predicted

Surprise                Blended Mean Change               Predicted

Surprise                Blended Mean Change               Predicted


Revenue              59                         -0.4%     0.6%                             0.2%      0.3%                    0.5%               0.7%

EBITDA 88                         3.0%      1.6%                     2.3%      0.7%                    2.0%      1.8%

EPS       88                         1.8%      3.1%                     2.0%      1.4%                    3.0%      2.2%

Mean Recommendation Change

Recommendations            92                         -0.40


PETS has above avg core fundamental margins:

Growth Industry
Merchandise Margins 31.80% (0.70%) YoY
Gross Margin 35.15% 3.26% 4Q 54.05%
Operating Margin 18.56% 3.06% 4Q 3.02%
Net Margin 11.90% 2.12% 4Q 2.21%
Asset Turnover 0.60 (3.28%) 4Q 0.44
ROE 8.21% 1.61% 4Q 1.12%
Debt/Equity 0.00% 4Q 45.46


PETS is undervalued relative to its peer group


  PETS       peers
LTM 24-Oct-17 NTM
PE 33.44 25.66 37.87
EV/EBITDA 19.12 15.81 18.04
Div Yield 2.18% 1.97% 0.00%
EV/Sales 3.22 2.94 3.64
P/CF 18.64 18.03 29.67
P/B 9.00 8.51 5.23


Meanwhile, Short interest has grown to a very high level of over 31% of the float.

*Model valuation assumptions : 1.50 ttm eps, 5yr cagr 15%, 25xpe, 10% discount rate.


ABOUT Smart Screens

Smart Screens
Powered by Sabrient

Key Features

  1. Based on models that have long displayed excellent market-beating performance, in collaboration with Sabrient, our smart screens employ proven fundamentals-based multifactor quantitative models as the underlying engine for a variety of indexes, actionable idea lists, and model portfolios.
  2. We look “under the hood” at the quality and sustainability of reported earnings in order to help avoid companies at higher risk of performance-offsetting meltdowns due to earnings misses or restatements.
  3. Sabrient-powered Smart Screens utilize a proprietary Earnings Quality Rank (EQR), a pure accrual accounting risk assessment signal that can be used for fundamental screening or within quant models as both a screening and scoring factor.
  4. Sabrient’s quant methodology is somewhat unique among quant shops:
  • Rather than employing a lot of multiple regression, data mining, optimization, and curve fitting, they use a scientific hypothesis testing approach to build models that make sense.
  • Sabrient uses relevance scoring rather than filtering and sequential elimination.
  • Sabrient employs a strong forward-looking emphasis rather than just screening for historical trends. This relies upon sell-side earnings projections, including the consensus estimates as well as the internal dynamics of those estimates, i.e., the number of analysts revising up or down and the magnitude of those revisions.


Singular Staff


For more information call us at 818-222-6234 or email

This report has been prepared by Singular Research, a wholly owned subsidiary of Millennium which is an investment advisor registered in the State of California. Singular Research receives fees from Millennium for the right to use and distribute research reports prepared by Singular Research. Millennium does and seeks to do business with companies covered in Singular Research’s research reports. Millennium may receive fees from issuers that are the subject of research reports prepared by Singular Research for investor and public relations and other marketing-related services provided to such issuers by Millennium. As a result, investors should be aware that Singular Research and Millennium may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.